US-based Gilead Sciences has roped in four Indian pharmaceutical companies to develop and market three new generic HIV/AIDS drugs in over 100 countries. The drugs are currently in final stages of ...

India's pharmaceutical industry is urging its government to negotiate with Washington from a “position of power” on tariffs ...

With over thirty years experience in pharma Tapan Ray has a broad overview of how Indian pharma currently ... It is good for the country that 100% FDI in the pharmaceutical sector has remained ...

Tariffs should not influence decisions at Indian drug companies, Cipla's top executive said on Friday, as the industry braces for U.S. President Donald Trump's plans to tax pharmaceutical imports.

The NMC’s intention is definitely noble but it is important to focus on quality of medicines, branded or generics. Icra said it has taken into account a sample set of 25 Indian drug firms, which ...

Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a JPMorgan report. Essentially, Indian pharmaceutical companies have the potential to ...

Indian pharmaceutical companies will be able to retain their dominant market share in the US in selling generic drugs even if President Donald Trump imposes high tariffs because they are “highly ...